Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women

Circulation

Volumn 93, Issue 10, 1996, Pages 1928-1937

  Guetta, Victor ^a   Cannon III, Richard O ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

atherosclerosis; drugs; hormones; lipoproteins; women

Indexed keywords

ANTILIPEMIC AGENT; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FEMALE; HEMOSTASIS; HORMONE ACTION; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 0029882260     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.10.1928     Document Type: Review

References (153)

1. National Center for Health Statistics. Vital Statistics of the United States, 1989. Vol II: Mortality, Part A. Washington, DC: Government Printing Office; 1993. DHHS Publication (PHS) 93-1101.
2. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
3. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102-1109.
4. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
5. Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
6. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med. 1992;117:1038-1041.
7. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062-1071.
8. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-1593.
9. Pilote L, Hlatky MA. Attitudes of women toward hormone replacement therapy and prevention of heart disease. Am Heart J. 1995;129:1237-1238.
10. Sullivan JM, VanderZwaag R, Hughes JP, Kroetz FW, Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med. 1990; 150:2557-2562.
11. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 1993;98:83-90.
12. Campos H, McNarara SR, Wilson PWF, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1988;67:30-35.
13. Brown SA, Hutchinson R, Morrisett JD, Boerwinkle E, Davis CE, Gotto AM, Patsch W. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb. 1993;13:1139-1158.
14. Tikkanen MJ, Nikkila EA, Vartianen E. Natural oestrogen as an effective treatment for type-II hyperlipoproteinemia in postmenopausal women. Lancet. 1978;2:490-491.
15. Granfone A, Campos H, McNamara JR, Schaefer MM, Lamon-Fava S, Ordovas JM, Schaefer EJ. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism. 1992;41:1193-1198.
16. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991;73:925-930.
17. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
18. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA. 1995;273:199-208.
19. Kushwaha RS, Born KM. Effect of estrogen and progesterone on the hepatic cholesterol 7α-hydroxylase activity in ovariectomized baboons. Biophys Acta. 1991;1084:300-302.
20. Windler E, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL. The estradiol-stimulated lipoprotein receptor of rat liver. J Biol Chem. 1980;225:10464-10471.
21. Tikkanen MJ, Nikkila EA, Kussi T, Sipinens S. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab. 1982;54: 1113-1117.
22. Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol. 1994;5:236-240.
23. Soma MR, Osnago-Gadda I, Paoletti R, Fumagalli R, Morrisett JD, Meschia M, Crosignani P. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 1993;153:1462-1468.
24. Jenner JL, Orodovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF, Castelli WP, Schaefer EJ. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation. 1993;87:1135-1141.
25. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA. 1993; 270:2195-2199.
26. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, Abolafia JM, Lippel K, Levy RI. Lipoprotein (a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994; 271:999-1003.
27. Sacks FM. Is there anything to add to our lipid risk factors for coronary heart disease? Am J Cardiol. 1995;75:1263-1264.
28. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1995;332:512-521.
29. Hough JL, Zilversmit DB. Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits. Arteriosclerosis. 1986;6:57-63.
30. Clarkson TB, Shively CA, Morgan TM, Koritnik DR, Adams MR, Kaplan JR. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol. 1990;75:217-222.
31. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis. 1990;10:1051-1057.
32. Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
33. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
34. Vanhoutte PM. The endothelium: modulator of vascular smooth muscle tone. N Engl J Med. 1988;319:512-513.
35. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol. 1986;250: H1145-H1149.
36. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
37. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228-234.
38. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991;83:391-401.
39. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 1993;91: 29-37.
40. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
41. Zeiher AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation. 1995;92:1094-1100.
42. Chowienczyk PJ, Watts GF, Cockroft JR, Brett SE, Ritter JM. Sex differences in endothelial function in normal and hypercholesterolaemic subjects. Lancet. 1994;334:305-306.
43. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994;24:471-476.
44. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther. 1988;244:19-22.
45. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990; 81:1680-1687.
46. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 1992;20:452-457.
47. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol. 1991;104:1033-1037.
48. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol. 1993;263:H271-H272.
49. Chester AH, Jiang C, Borland JA, Yacoub MH, Collins P. Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. Coron Artery Dis. 1995;6: 417-422.
50. 2 in porcine coronary artery. Circulation. 1995;91:2619-2626.
51. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 1994;89:52-60.
52. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 1994;89:2545-2551.
53. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelium-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen therapy. Am J Cardiol. 1994;73:951-952.
54. Collins P, Rosano GMC, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17β-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 1995; 92:24-30.
55. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation. 1994;90:786-791.
56. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Effects of estrogen therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol. 1995;75:264-268.
57. Lip GYH, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens. 1994;8:491-494.
58. Lieberman EH, Gebhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936-941.
59. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987;80:1808-1811.
60. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet. 1993;341:1496-1500.
61. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89: 2519-2524.
62. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol lowering-therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
63. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
64. Goode GK, Heagerty AM. In vitro responses of human peripheral small arteries in hypercholesterolemia and effects of therapy. Circulation. 1995;91:2898-2903.
65. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet. 1993;342:133-136.
66. Lerman A, Webster MWI, Chesebro JH, Edwards WD, Wei C-M, Fuster V, Burnett JC. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 1993;88: 2923-2928.
67. Polderman KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verbeugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993;118:429-432.
68. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A. 1992;89:11259-11263.
69. Van Buren GA, Yang D, Clark KE. Estrogen-induced uterine vasodilatation is antagonized by L-nitroarginine methyl ester an inhibitor of nitric oxide synthesis. Am J Obstet Gynecol. 1992;167: 828-833.
70. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Scid U S A. 1994;91:5212-5216.
71. Schray-Utz B, Zeiher AM, Busse R. Expression of constitutive NO synthase in cultured endothelial cells is enhanced by 17β-estradiol. Circulation. 1993;88(suppl I):I-80. Abstract.
72. Caulin-Glaser TL, Sessa W, Sarrel P, Bender J. The effect of 17β-estradiol on human endothelial cell nitric oxide production. Circulation. 1994;90(suppl I):I-30. Abstract.
73. Sayegh HS, Ohara Y, Navas JP, Peterson TE, Dockery S, Harrison DG. Endothelial nitric oxide synthase regulation by estrogens. Circulation. 1993;88(suppl I):I-80. Abstract.
74. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate. Hypertension. 1995;25:848-853.
75. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
76. Cooke JP, Tsao PS. Cytoprotective effects of nitric oxide. Circulation. 1993;88:2451-2454.
77. Steinberg D, Parasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
78. Berliner JA, Territo MC, Savanian A, Ramin S, Kim JA, Bamshad B, Emerson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85:1260-1266.
79. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci USA. 1987;84:7725-7729.
80. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-1449.
81. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-1456.
82. Yagi K, Komura S. Inhibitory effect of female hormones on lipid peroxidation. Biochem Int. 1986;13:1051-1055.
83. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett. 1987;210:37-39.
84. Yoshino K, Komura S, Watanabe I, Nakagawa Y, Yagi K. Effect of estrogens on serum and liver lipid peroxide levels in mice. J Clin Biochem Nutr. 1987;3:233-240.
85. Nakano M, Sugioka K, Naito I, Takekoshi S, Niki E. Novel and potent biological antioxidants on membrane phospholipid peroxidation: 2-hydroxy estrone and 2-hydroxy estradiol. Biochem Biophys Res Commun. 1987;142:919-924.
86. Mukai K, Daifuku K, Yokoyama S, Nakano M. Stopped-flow investigation of antioxidant activity of estrogens in solution. Biochim Biophys Acta. 1990;1035:348-352.
87. Huber LA, Scheffler E, Poll T, Ziegler R, Dresel HA. 17β-Estradiol inhibits LDL oxidation and cholesterol ester formation in cultured macrophages. Free Radic Res Commun. 1990;8: 167-173.
88. Maziere C, Auclair M, Ronveaux M-F, Salmon S, Santus R, Maziere J-C. Estrogens inhibit copper and cell-mediated modification of low density lipoprotein. Atherosclerosis. 1991;89:175-182.
89. Rifici VA, Khachadurian AK. The inhibition of low-density lipoprotein oxidation by 17β-estradiol. Metabolism. 1992;41: 1110-1114.
90. Negre-Salvayre A, Pieraggi M-T, Mabile L, Salvayre R. Protective effect of 17β-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis. 1993;99:207-217.
91. Subbiah MTR, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab. 1993;77:1095-1097.
92. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994;343:269-270.
93. Guetta V, Panza JA, Waclawiw MA, Cannon RO. Effect of combined 17β-estradiol and vitamin E on low-density lipoprotein oxidation in postmenopausal women. Am J Cardiol. 1995;75: 1274-1276.
94. Keaney JF, Shwaery GT, Xu A, Nicolosi RJ, Loscalzo J, Foxall TL, Vita JA. 17β-Estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation. 1994;89:2251-2259.
95. Niki E. Antioxidants in relation to lipid peroxidation. Chem Phys Lipids. 1987;44:227-253.
96. Esterbauer H, Wag G, Puhl H. Lipid peroxidation and its role in atherosclerosis. Br Med Bull. 1993;49:566-576.
97. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. Role of nitric oxide in the endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation. 1993;88:2541-2547.
98. Mangin EL, Kugiyama K, Nguy JH, Kerns SA, Henry PD. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res. 1993; 72:161-166.
99. Shimokawa H, Flavahan NA, Vanhoutte PM. Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries. Circulation. 1991;83:652-660.
100. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases superoxide anion production. J Clin Invest. 1993;91: 2546-2551.
101. Minor RL, Myers PR, Guerra R, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest. 1990;86:2109-2116.
102. Gilligan DG, Sack M, Guetta V, Casino PR, Quyyumi AA, Rader DJ, Panza JA, Cannon RO. Effect of antioxidant vitamins on low-density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol. 1994;24:1611-1617.
103. The Coronary Drug Project Research Group. The Coronary Drug Project: initial findings leading to modifications of its research protocol. JAMA. 1970;214:1303-1313.
104. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
105. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 1995;91:1952-1958.
106. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, Yasue H. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from cndothelial cells. Circ Res. 1993;73:335-343.
107. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem. 1991;266:2459-2465.
108. Fischer GM. In vivo effects of estradiol on collagen and elastin dynamics in rat aorta. Endocrinology. 1972;91:1227-1232.
109. Wolinsky H. Effects of estrogen and progesterone treatment on the response of the aorta of male rats to hypertension: morphological and chemical studies. Circ Res. 1972;30:341-349.
110. Fischer GM, Swain ML. Effect of sex hormones on blood pressure and vascular connective tissue in castrated and noncastrated male rats. Am J Physiol. 1977;232:H617-H621.
111. Beldekas JC, Smith B, Gerstenfeld LC, Sonenshein GE, Franzblau G. Effect of 17β-estradiol on the biosynthesis of collagen in cultured bovine aortic smooth muscle cells. Biochemistry. 1981;20:2162-2167.
112. Fischer GM, Swain ML. In vivo effects of sex hormones on aortic elastin and collagen dynamics in castrated and intact rats. Endocrinology. 1978;102:92-97.
113. Fischer-Dzoga K, Wissler RW, Vesselinovitch D. The effect of estradiol on the proliferation of rabbit aortic medial tissue culture cells induced by hyperlipemic serum. Exp Mol Pathol. 1983;39: 355-363.
114. Vargas R, Wroblewska B, Rego A, Hatch J, Ramwell PW. Oestradiol inhibits smooth muscle proliferation of pig coronary artery. Br J Pharmacol. 1993;109:612-617.
115. Mitchell HC. Effect of estrogens and a progestogen on platelet adhesiveness and aggregation in rabbits. J Lab Clin Med. 1974;83: 79-89.
116. Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol. 1977;232:H381-H385.
117. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK, Schnaper HW. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation. 1995;91:755-763.
118. Ylikorkala O, Kuusi T, Tikkanen MJ, Viinikka L. Desogestreland levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. J Clin Endocrinol Metab. 1987;65: 1238-1242.
119. Sylvester JT, Gordon JB, Malamet RL, Wetzel RC. Prostaglandins and estradiol-induced attenuation of hypoxic pulmonary vasoconstriction. Chest. 1985;88:252S-254S.
120. Chang W, Nakao J, Orimo H, Murota S. Stimulation of prostaglandin cyclooxygenase and prostaglandin synthase activities by estradiol in rat aortic smooth muscles. Biochim Biophys Acta. 1980; 620:472-482.
121. Fogelberg M, Vesterqvist O, Diczfalusy U, Henriksson P. Experimental atherosclerosis: effects of oestrogen and atherosclerosis on thromboxane and prostacyclin formation. Eur J Clin Invest. 1990;20:105-110.
122. Nordo Berge L, Hansen J-B, Svensson B, Lyngmo V, Nordoy A. Female sex hormones and platelet/endothelial cell interactions. Haemostasis. 1990;20:313-320.
123. David M, Griesmacher A, Muller MM. 17α-Ethinyloestradiol decreases production and release of prostacyclin in cultured human umbilical vein endothelial cells. Prostaglandins. 1989;38: 431-438.
124. Redmond EM, Cherian MN, Wetzel RC. 17β-Estradiol inhibits flow- and acute hypoxia-induced prostacyclin release from perfused endocardial endothelial cells. Circulation. 1994;90: 2519-2524.
125. Proudler AJ, Ahmed AIH, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-eonverting-enzyme activity in postmenopausal women. Lancet. 1995;3461:89-90.
126. Hamlet MA, Rorie DK, Tyce GM. Effects of estradiol on release and disposition of norepinephrine from nerve endings. Am J Physiol. 1980;239:H450-H456.
127. Colucci WS, Gimbrone MA, McLaughlin MK, Halpern W, Alexander RW. Increased vascular catecholamine sensitivity and α-adrenergic receptor affinity in female and estrogen-treated male rats. Circ Res. 1982;50:805-811.
128. Miller VM, Vanhoutte PM. 17β-Estradiol augments endothelium-dependent contractions to arachidonic acid in rabbit aorta. Am J Physiol. 1990;258:R1502-R1507.
129. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol. 1987;94: 620-635.
130. Falkeborn M. Persson I, Adami H-O, Bergstrom R, Eaker E, Mohsen HLR. Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 1992;99:821-828.
131. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994;154: 1333-1339.
132. Miller VM, Vanhoutte PM. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol. 1991;261:R1022-R1027.
133. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 1994;24: 1757-1761.
134. Jacobs DR, Mebane IL, Bangdiwala SI. Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131:32-47.
135. Kleinveld HA, Demacker PNM, De Haan AFJ, Stalenhoff AFH. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-COA rcductase inhibitors. Eur J Clin Invest. 1993; 23:289-295.
136. Lavy A, Brook GJ, Danker G, Amotz AB, Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism. 1991;40:794-799.
137. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1993;1165: 335-338.
138. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system: diminution of synthesis of plasminogen activator inhibitor type I. Circulation. 1992;85:1888-1893.
139. Brown SL, Sobel BE, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type I by niacin: a potential link between lipid-lowering and fibrinolysis. Circulation. 1995;92: 767-772.
140. Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K, Ohiwa M, Tamaki S, Tanigawa M, Kageyama S, Deguchi K, Nakano T, Shirakawa S, Suzuki K. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol. 1993;44:112-116.
141. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
142. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med. 1995;332:1758-1766.
143. Brensike JR, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ, Fished MR, Friedman L, Friederwald W, Detre KM, Epstein SE. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of the NHLBI, Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
144. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336:129-133.
145. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
146. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lesperance J, for the CCAIT Study Group. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation. 1995;92:2404-2410.
147. Trial of clofibrate in the treatment of ischaemic heart disease: five-year study by a group of physicians of the Newcastle-Upon-Tyne region. BMJ. 1971;790:767-775.
148. The Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. BMJ. 1971;790: 775-784.
149. Rosenhamer G, Carlson LA. Effect of combined clonbrate-nicotinic acid treatment in ischemic heart disease. Atherosclerosis. 1980;37:129-138.
150. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston A, Smink RO, Sawin HS, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 1990;323:946-955.
151. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
152. Gotto AM. Lipid-lowering, regression, and coronary events: a review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, seventh council meeting. Circulation. 1995;92:646-656.
153. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.